Clinical Implications of Technical Performance in Medical Genome Sequencing

Published

March 2, 2016

Author(s)

Justin M. Zook, James Priest, Rachel Goldfeder, Megan Grove, Daryl Waggott, Matthew Wheeler, Euan Ashley, Marc L. Salit

Abstract

As next-generation sequencing is becoming routinely applied to clinical care, the predictive characteristics and limitations of whole exome and whole genome sequencing need to be well-understood. The Genome in a Bottle Consortium has recently published a set of benchmark SNP, indel, and homozygous reference genotypes for the pilot candidate whole genome NIST Reference Material based on NA12878. We use these benchmark calls to assess the sensitivity and positive predictive value for two representative sequencing pipelines from this single individual. We observe that the accuracy of a variant call depends on the genomic region, variant type, and read depth, and varies by analytical pipeline. We also identify sites that are prone to sequencing errors for this genome, including thousands that are present in publicly available variant databases. We examine the clinical impact of mandatory reporting of secondary findings, highlighting a false positive variant found in BRCA2. Together, these data illustrate the necessity of applying and reporting technical benchmarks to ensure accurate and judicious interpretation of next-generation DNA sequencing results in the clinic.

Citation

American Journal of Human Genetics

Pub Type

Journals

Download Paper

https://doi.org/10.1186/s13073-016-0269-0

Citation

Zook, J. , Priest, J. , Goldfeder, R. , Grove, M. , Waggott, D. , Wheeler, M. , Ashley, E. and Salit, M. (2016), Clinical Implications of Technical Performance in Medical Genome Sequencing, American Journal of Human Genetics, [online], https://doi.org/10.1186/s13073-016-0269-0 (Accessed November 20, 2024)